The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin Files for Approval Based on Public Knowledge for IM Administration and Dosage for Leunase
October 5, 2012
- Ono Conducts Nation’s First Microdosing Study for New Drug Candidate
October 5, 2012
- Bayer Files for Fosrenol for Patients with CKD in Preservation Period
October 5, 2012
- MTPC Outsources All Logistics Operations
October 5, 2012
- Takeda, Lundbeck File NDA for Major Depressive Disorder Treatment Vortioxetine in US
October 4, 2012
- Baxter Files for Approval in Japan for Cell Culture Influenza Vaccine
October 4, 2012
- Takeda Initiates Drug Discovery Collaboration with Advinus of India to Boost Research Productivity
October 4, 2012
- Daiichi Sankyo Discontinues PIII Study of ARQ197 in Patients with NSCLC
October 4, 2012
- Sanofi Takes Over 3 Genzyme Products
October 3, 2012
- Astellas Strikes Deal to License JAK Inhibitor to Janssen Biotech Outside Japan
October 3, 2012
- Seikagaku Completes New Production Facilities for Gel-One to Meet Increasing Demand in US
October 3, 2012
- Shionogi Acquires Worldwide Rights for Cholesterol Absorption Inhibitor from Kotobuki
October 3, 2012
- “Comprehensive Strengths” Have Been Biggest Result of Alliance with Roche: Chairman Nagayama of Chugai
October 3, 2012
- Takeda Receives Approval for Hyperlipidemia Drug Lotriga
October 2, 2012
- Bayer Yakuhin Obtains Approval for VEGF Inhibitor Eylea, Santen to Distribute Product
October 2, 2012
- Sanwa Kagaku, Kowa Obtain Approval for DPP-4 Inhibitor Suiny, to Market Under One Brand Name
October 2, 2012
- Qol Reaches Agreement for Approximately Half of Its Price Negotiations with Wholesalers
October 1, 2012
- Mochida Enters Generic Anticancer Drug Market with Hospira Products
October 1, 2012
- Osaka District Court Rules Against Takeda in Actos Patent Dispute with 8 Generic Drug Makers
October 1, 2012
- Novartis Obtains Approval for COPD Drug Seebri, Copromotion Planned with Eisai
October 1, 2012
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…